Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Burn
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 3
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Phase I single FT1050 (16,16-dimethyl prostaglandin E2) ex vivo-modulated umbilical cord blood unit after reduced intensity conditioning
Acute Myelogenous Leukemia · Non-Hodgkin's Lymphoma · Hodgkin's Disease · CLL · ALL
Enrolment: 10 · Results not recorded
Phase 1 single ProHema-CB product (dmPGE2 ex vivo-modulated cord blood) in paediatric inherited metabolic disorders
Metabolic Disorders
Enrolment: 1 · Results not recorded
Phase 1 single ProHema-CB product after myeloablative conditioning in paediatric haematologic malignancies
Hematologic Malignancies
Enrolment: 3 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatBurnUnspecifiedLewisMaleAfter burn injury
Model: Thermal burn with septic (Pseudomonas) challenge
16,16-dimethyl-prostaglandin E2 increased gut translocation of bacteria, had no significant effect on resting metabolic rate, and increased serum acute-phase proteins in rats with non-septic burns. The authors concluded prostaglandin E may have both detrimental and beneficial effects.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.